Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Curr Drug Metab. 2010 Oct;11(8):659–666. doi: 10.2174/138920010794233495

Figure 1.

Figure 1

5-MeO-DMT biotransformation and the metabolic interactions with harmaline. O-demethylation of 5-MeO-DMT by CYP2D6 produces an active metabolite bufotenine. Both 5-MeO-DMT and bufotenine are readily deaminated by MAO-A to indoleacetic acid derivatives. The MAOI harmaline, which is inactivated by CYP2D6, blocks the deamination metabolism of 5-MeO-DMT and bufotenine.